Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 12:13:1188017.
doi: 10.3389/fonc.2023.1188017. eCollection 2023.

Association between serum γ-glutamyl transferase and advanced colorectal adenoma among inpatients: a case-control study

Huijie Wang #  1 , Huanwei Zheng #  2 , Xu Cao  1 , Ping Meng  2 , Jinli Liu  1 , Haiying Zuo  3 , Teng Zhang  4 , Zhichao Wang  3
Affiliations

Association between serum γ-glutamyl transferase and advanced colorectal adenoma among inpatients: a case-control study

Huijie Wang et al. Front Oncol. .

Abstract

Emerging evidence suggests a link between γ-glutamyl transferase (GGT) and various malignancies. However, the relationship between GGT and advanced colorectal adenoma, a critical precursor to colorectal cancer, remains unclear. This study aimed to elucidate this relationship. We conducted a single-center retrospective study from April 2015 to June 2022, enrolling 3534 inpatients including 525 cases and 3009 controls. Data were extracted from the electronic medical records, encompassing clinicodemographic characteristics, co-morbidities, and several blood biochemical indicators. Utilizing logistic regression and curve fitting, we explored the relationship between GGT and advanced colorectal adenoma. After adjustment for confounding factors, we found that for each 20-unit increase in GGT, the risk of advanced colorectal adenoma increased by 6% (OR= 1.06 [1.01-1.12]). Moreover, individuals with high GGT levels (≥50 U/L) had a 61% higher risk of advanced colorectal adenoma compared to those with low GGT levels (<50 U/L) (OR=1.61 [1.13-2.31]). Subgroup analysis demonstrated the robustness of these findings across subjects with different characteristics. High GGT levels were associated with higher odds of advanced colorectal adenoma. Our findings suggest that elevated GGT levels may serve as a potential diagnostic marker for advanced colorectal adenoma, providing new insights into its screening strategies.

Keywords: advanced colorectal adenoma; association; case-control study; retrospective study; serum γ-glutamyl transferase.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of participants.
Figure 2
Figure 2
Association between γ-glutamyl transferase and advanced colorectal adenoma among inpatients. Odds ratio (OR) was adjusted for age, sex, smoking status, drinking status, weight, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, albumin, creatinine, uric acid, triglyceride, high-density lipoprotein, low-density lipoprotein, urea, ischemic cerebrovascular disease, diabetes mellitus, hypertension, and coronary heart disease. The γ-glutamyl transferase level was transformed using natural logarithm conversion.
Figure 3
Figure 3
Subgroup analyses of the γ-glutamyl transferase (per 20 U/L) and advanced colorectal adenoma among inpatients. Each subgroup was adjusted for age, sex, weight, drinking status, smoking status, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, albumin, creatinine, uric acid, triglyceride, high-density lipoprotein, low-density lipoprotein, urea, ischemic cerebrovascular disease, diabetes mellitus, hypertension, and coronary heart disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bray F. Transition in human development and the global cancer burden. World Cancer Rep (2014), 54–68.
    1. Fidler MM, Soerjomataram I, Bray F. A global view on cancer incidence and national levels of the human development index. Int J Cancer (2016) 139(11):2436–46. doi: 10.1002/ijc.30382 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin Med J (2021) 134(7):783–91. doi: 10.1097/cm9.0000000000001474 - DOI - PMC - PubMed
    1. Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. . Cancer statistics in China and United States 2022: Profiles, trends, and determinants. Chin Med J (Engl) (2022) 135(5):584–90. doi: 10.1097/cm9.0000000000002108 - DOI - PMC - PubMed

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Hebei Administration of Traditional Chinese Medicine (grant number 2023145).